Nanomedicine (London, England) · 2026
Extracellular vesicles targeting EGFR inhibit MAOA expression and activity by delivering curcumin for the treatment of asthma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guo Rui, Wang Yinghui, Hao Guojie, Li Yan, Li Pan, Qiao Liang, Lin Juntang
Аннотация
AIMS: To investigate whether curcumin (CUR) delivered by EGFR-targeted extracellular vesicles (EVs) alleviates asthma and to explore the underlying mechanism.
MATERIALS AND METHODS: CUR was loaded into mouse bone marrow mesenchymal stem cell‑derived EVs. A bispecific fusion protein, ZEGFR‑CP05 (EGFR‑specific affibody linked to a CD63‑binding peptide), was used to modify EVs. Therapeutic efficacy and targeting were evaluated in an ovalbumin (OVA)‑induced acute asthma mouse model.
RESULTS: ZEGFR‑CP05‑EVs showed enhanced lung accumulation. In asthmatic mice, ZEGFR‑CP05‑EVs‑CUR reduced airway inflammation, goblet cell hyperplasia, collagen deposition, and EGFR expression. Network pharmacology combined with experimental validation identified monoamine oxidase A (MAOA) as a novel target. Treatment suppressed MAOA expression and activity, restored serotonin (5‑HT) levels, and decreased reactive oxygen species (ROS) generation.
CONCLUSIONS: ZEGFR‑CP05‑EVs mediated curcumin delivery alleviates asthma pathology by inhibiting MAOA, highlighting a promising therapeutic strategy.
MATERIALS AND METHODS: CUR was loaded into mouse bone marrow mesenchymal stem cell‑derived EVs. A bispecific fusion protein, ZEGFR‑CP05 (EGFR‑specific affibody linked to a CD63‑binding peptide), was used to modify EVs. Therapeutic efficacy and targeting were evaluated in an ovalbumin (OVA)‑induced acute asthma mouse model.
RESULTS: ZEGFR‑CP05‑EVs showed enhanced lung accumulation. In asthmatic mice, ZEGFR‑CP05‑EVs‑CUR reduced airway inflammation, goblet cell hyperplasia, collagen deposition, and EGFR expression. Network pharmacology combined with experimental validation identified monoamine oxidase A (MAOA) as a novel target. Treatment suppressed MAOA expression and activity, restored serotonin (5‑HT) levels, and decreased reactive oxygen species (ROS) generation.
CONCLUSIONS: ZEGFR‑CP05‑EVs mediated curcumin delivery alleviates asthma pathology by inhibiting MAOA, highlighting a promising therapeutic strategy.